Introduction Chimeric antigen receptor (CAR) T-cell therapy produces high overall response rates (ORR) and can induce durable remissions in relapsed/refractory multiple myeloma (MM), raising the possibility of long-term disease control or cure. However, standard response assessments have limited ability to identify patients with exceptional outcomes early after CAR T therapy. Bone marrow-based [...]

Introduction Ciltacabtagene Autoleucel (cilta-cel) produces high response rates in multiple myeloma (MM), but most patients eventually relapse, emphasizing the need for sensitive, frequent, and reliable minimal residual disease (MRD) monitoring. Traditional bone marrow-based MRD assessments face multiple challenges: they can miss disease due to spatial heterogeneity, suffer from hemodilution, are difficult to [...]

Introduction Minimal residual disease (MRD) negativity is a critical prognostic factor in multiple myeloma (MM), but conventional monitoring relies on invasive bone marrow (BM) testing and may miss disease due to spatial heterogeneity. EasyM is a mass spectrometry-based blood assay that tracks patient-specific M-protein peptides in peripheral blood, enabling frequent, non-invasive MRD [...]

Introduction Bone marrow (BM)-based minimal residual disease (MRD) has been established as one of the most important dynamic prognostic markers in multiple myeloma (MM). However, the necessity of bone marrow biopsies limits the feasibility of frequent MRD monitoring. Consequently, there is an urgent unmet need for peripheral blood-based MRD testing for serial [...]